| abstract |
Thrombogenic disorders (for example, but not limited to, atrial fibrillation, stroke, long-term intermittent neuropathy (PRIND), transient ischemic attack (TIA), atherosclerotic cerebrovascular disease ( CVD) and / or coronary heart disease), a method for selecting a patient at risk for a thrombogenic disorder, an agent for treating or preventing a thrombogenic disorder Methods of identification are provided as well as methods of producing pharmaceuticals and diagnostic agents by using the TAFI-Ile347 polymorphism. Measuring or detecting inhibition of TAFI-Ile347 enzyme activity or inhibition of TAFI-Ile347 gene expression by a test compound, treatment of stroke or transient ischemic attack (TIA) and / or A method of identifying drugs for prevention. [Selection figure] None |